Spherix Global Insights

April 07, 2021

Tecfidera, Gilenya and Ocrevus Losing Favor as Switch Therapies in US, Spherix Finds

From: Multiple Sclerosis News Today

By: Marta Figueiredo, PhD

Multiple Sclerosis News Today

Tecfidera (dimethyl fumarate), Gilenya (fingolimod), and Ocrevus (ocrelizumab) are losing ground to more recent therapies among U.S. multiple sclerosis (MS) patients switching treatment, according to the latest Spherix Global Insights’ report…(read more).